Introduction
============

Gastric cancer (GC) is the fifth most common type of cancer worldwide with 950,000 new cases diagnosed and more than 720,000 deaths occurred in 2012 [@B1],[@B2]. GC is particularly prevalent in China with morbidity and mortality ranking 2^nd^ after lung cancer, posing severe threat to mankind[@B3]. Although many therapeutic strategies are applied to GC, the prognosis is still poor. So far, there are few methods recognized for predicting clinical outcomes of GC. Although tumor-node-metastasis (TNM) staging has been regarded as an important predictor of the prognosis, the fact that patients with the same TNM staging having different prognoses suggests genetic variants between individuals may play an important role[@B4], [@B5]. Therefore, identifying novel genetic biomarkers for GC prognosis has the vital clinical significance. Single nucleotide polymorphisms (SNPs), one of most common type of genetic variants among individuals, play a vital role in GC development, invasion, and prognosis[@B5]-[@B8]. Therefore, we speculated that SNPs may be valuable as biomarkers for GC prognosis.

The mammalian target of rapamycin (mTOR) signaling pathway is involved in cell growth regulation, proliferation and metabolism. Deregulation of the pathway commonly exists in most of human cancers[@B9]-[@B11]. There are two different forms of mTOR in mammalian cells: mTOR complex 1 (mTORC1) and mTORC2. In particular, mTORC1 is a central regulator of the mTOR pathway that contains mTOR, mammalian lethal with sec-13 protein 8 (MLST8) and the regulatory-associated protein of mTOR (RPTOR), and this pathway is sensitive to rapamycin inhibition[@B12]. The upstream signaling pathways of mTORC1 include phosphoinositide 3-kinase (PI3K)/AKT pathway and Ras/MAPK pathway. The eIF4E binding protein 1 (4E-BP1) and ribosomal protein S6 kinases (S6K1) are the main downstream elements of mTORC1[@B13]. The main functions of mTORC1 include supporting cell growth, proliferation, cell metabolism and angiogenesis[@B14]-[@B16]. Previous studies have shown the activation of PI3K/AKT/mTOR signaling pathway has an effect on the prognosis for GC patients[@B17]-[@B19]. In addition, it was demonstrated that genetic variants within mTORC1 genes were associated with esophageal cancer and GC risk[@B20], [@B21].

There are few published studies that have addressed the role of genetic variants in mTORC1 genes in GC prognosis. Considering the mTORC1 plays an important role in the development of GC, we evaluated the associations between potential functional SNPs in mTORC1 genes and GC prognosis in Chinese populations. Additionally, as we know, GC is a complex genetic disease, so we tried to explore the joint effects of multiple SNPs on GC prognosis.

Materials and Methods
=====================

Study population
----------------

A total of 197 GC patients who underwent a surgical resection were recruited from Xin Hua Hospital affiliated to Shanghai Jiaotong University School of Medicine (Shanghai, China) between April 2010 and December 2012. All patients were newly diagnosed with gastric adenocarcinoma confirmed by histopathological examinations. None of these patients had chemotherapy or radiotherapy prior to surgery. Paraffin-embedded tissues of patients were available. The information of clinical and pathological data, such as age, sex, tumor size, differentiation, depth of invasion and drinking status, were acquired by patients\' medical records. The stage of GC was evaluated according to the tumor-node-metastasis (TNM) classification of the American Joint Commission on Cancer (AJCC) in 2010 (the 7th edition). All the patients were followed up through the outpatient service and telephone calls. The last time of follow-up was December 2015. The survival time was defined as the time between the date of surgical operation and the date of the last contact or cancer-related death. This study was approved by the Medical Ethics Committee of the hospital.

SNP selection and Genotyping
----------------------------

Eight SNPs were selected as described previously[@B20]. In brief, we searched the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/>), HapMap database (<http://www.hapmap.org>) and SNPinfo (<http://snpinfo.niehs.nih.gov/>) to choose potentially functional SNPs of interest. The selection criteria were as follows: 1) minor allele frequency (MAF) reported in HapMap was ≥ 5% in Chinese Han, Beijing (CHB); 2) located in the regulatory region of genes; 3) affecting the function of transcription factor binding site (TFBS) or the microRNA binding site; 4) the linkage disequilibrium (LD) coefficient r[@B2] was less than 0.8. Finally, we identified eight SNPs (rs2536 T\>C and rs1883965 G\>A for *mTOR,* rs3160 T\>C and rs26865 A\>G for *MLST8,* rs3751934 C\>A, rs1062935 T\>C, rs3751932 T\>C and rs12602885 G\>A for*RPTOR)* for the study. Among them, five SNPs (rs2536 T\>C, rs3160 T\>C, rs1062935 T\>C, rs3751934 C\>A, rs3751932 T\>C) located in the 3\'-untranslated region (3\'UTR) may affect the miRNA binding site function. For the remaining three SNPs, rs1883965 G\>A located in the intron region, rs26865 A\>G located in the 5\' near gene, rs12602885 G\>A located in the 5\'-untranslated region (5\'UTR) and all of them may affect the TFBS function.

Genomic DNA was extracted from paraffin embedded tissues using TIANamp FFPE DNA kit (TIANGEN, Beijing, China). The TaqMan SNP genotyping method based on 384-well ABI 7900HT Real-time PCR System (Applied Biosystems, Foster City, CA, USA) was performed. The genotypes were independently analyzed by two persons (XueWJ and ZhuXR) using SDS Software 2.4 (Applied Biosystems, Foster City, CA, USA). For quality control, two random samples and two blank controls using double distilled water instead of DNA were repeated and the results were 100% concordant.

Statistical Analysis
--------------------

Median survival time (MST) was used to estimate the time point when 50% studied patients died, and mean survival time was a statement about the observed time. When MST could not be calculated, mean survival time would be provided. Survival rates were determined using the Kaplan-Meier plots. Log-rank test was used to compare survival times across clinical features and different SNPs. HR and CIs were calculated by univariate and multivariate Cox hazards regression analyses for evaluating the factors of influencing survival time. The value of *P* \< 0.05 was considered statistically significant. All analyses were performed with SAS software (version 9.1; SAS Institute, Cary, NC).

Results
=======

Clinical characteristics of the study population
------------------------------------------------

A total of 197 gastric adenocarcinoma patients were included in the study. Among them, 129 (65.5%) were males and 68 (34.5%) were females. The median age was of 63 years (range, 25 to 88 years). According to the National Comprehensive Cancer Network (NCCN) clinical practice guideline, about 50% patients with Stage II or III received either cisplatin-containing regimen, taxel-containing regimen, 5-fluorouracil (5-FU)-containing regimen or a similar regimen in which 5-FU was replaced by tegafur/gimeracil/oteracil (S-1) as the adjuvant chemotherapy after surgery. During the follow-up period, 85 patients died from GC and three patients were lost to follow-up.

As shown in **Table [1](#T1){ref-type="table"}**, patients with tumor size \> 4cm, T3 or T4 invasion, Stage III/IV, vascular, lymphatic vessel and perineural invasion, chemotherapy were obviously at higher risk of death compared with those with tumor size ≤ 4cm, T1/T2 invasion, Stage I or II, without vascular, lymphatic vessel and perineural invasion, non-chemotherapy (adjusted *P* = 0.029, 0.017, \< 0.001, \< 0.001, 0.036, respectively). None of the other characteristics were associated with OS.

Associations between mTORC1 SNPs and OS of GC patients
------------------------------------------------------

As shown in **Table [2](#T2){ref-type="table"}**, in the single-locus analysis, we observed that *RPTOR* rs1062935 T\>C was significantly associated with an increased risk of poor GC prognosis (CC vs. TT/TC: adjusted HR = 1.71, 95% CI = 1.04-2.82, adjusted *P* = 0.033). However, these risk associations were not observed for other individual SNPs. In the combined analysis of all at-risk SNPs whose HR value was relatively high, we found that patients with more than three risk genotypes exhibited increased risk of death, compared to those with three or less risk genotypes (adjusted HR=2.44, 95% CI=1.30-4.58). Furthermore, a joint effect on the risk of GC death was in a risk-genotype dose-response manner, as evidenced by a significantly increased risk with an increasing number of observed risk genotypes (adjusted HR = 1.82, 95% CI = 0.61-5.46 for one risk genotype; adjusted HR = 2.71, 95% CI = 0.96-7.68 for two risk genotypes; adjusted HR = 2.31, 95% CI = 0.74-7.20 for three risk genotypes; adjusted HR = 4.69, 95% CI = 1.42-15.52 for four risk genotypes; adjusted HR = 9.53, 95% CI = 2.00-45.49 for five risk genotypes; *P*~trend~ = 0.002). As shown in **Figure [1](#F1){ref-type="fig"}** and**2**, Kaplan-Meier survival plots indicated cumulative risks for GC death associated with the presence of more than one through five risk genotypes (Log-rank *P* = 0.033, 0.015, respectively).

Discussion
==========

In the study, we firstly evaluated the effects of eight SNPs within three mTORC1 genes on survival of GC patients. We found that *RPTOR* rs1062935 CC variant increased risk of GC death, as well as patients with more than three risk genotypes, when compared to those with three or less risk genotypes.

MTORC1 plays a vital role in the mTOR signaling pathway and mTOR, MLST8 and RPTOR are the three major components of mTORC1. MTOR is a 289 kDa and evolutionarily conserved serine/threonine kinase which belongs to PI3K-related kinase family[@B22]. One study indicated that mTOR played an important role in regulating developmental and metabolic processes[@B23], while inhibiting mTOR might extend lifespan in animals[@B24]. MLST8, also known as GbetaL, is essential in activating the mTOR kinase. Except for directly stabilizing the active site of mTOR, MLST8 may be associated with other cellular proteins. Knockdown of *MLST8* inhibits tumor growth and invasiveness in some human cancers[@B25]-[@B27]. *RPTOR*, located at chromosome 17q25.3, acts as a scaffold role to recruit substrates to the mTOR kinase, thereby regulating the activity of mTOR[@B28], [@B29]. The deletion of *RPTOR* remarkably impaired acute myeloid leukemia (AML) progression through analyzing AML mouse models[@B30].

The mTORC1 signaling pathway involves in an increasing number of human diseases, such as diabetes, obesity, autoimmune disorders and cancers[@B31]. Some studies investigated the associations of genetic variants in mTORC1 pathway genes with susceptibility and survival of different cancers. For example, Chen M et al. identified that four SNPs (rs11653499, rs7211818, rs7212142 and rs9674559) in *RPTOR* were associated with an increased risk of bladder cancer[@B32], and He J et al. found that *mTOR* rs1883965 A variant genotypes were associated with an increased GC risk[@B21]. Although Zhu J et al. did not find main effects of five SNPs located in *PIK3R1* and *mTOR* with esophageal cancer risk using their own data, meta-analysis identified *mTOR* rs2295080 associated with cancer risk and the same effect occurred among subjects with one-to-three risk genotypes in further combined analysis. They also found the gene-environment interactions in esophageal carcinogenesis[@B33]. Similar to our results, their findings further validated the importance of genetic variations as well as mTOR signaling pathway on the development of cancer. It also reminds us gene-environment interactions may play a key role in determining clinical outcomes. A meta-analysis revealed *mTOR* rs11121704 TT was associated with poor clinical outcome, including death, metastasis and resistance to chemotherapy in patients with lung and esophageal cancer[@B34]. Piao Y et al. found two SNPs in *mTOR* and *AKT* genes increased GC susceptibility in the subgroups of man, H. pylori-negative individuals, and one SNP in *AKT* gene associated with lymph node metastasis but not with the survival in 203 cases[@B35]. Although researchers investigated different SNPs in different genes from different perspectives, and produced the final results differently, published results and ours both supported the hypothesis that SNPs in mTOR signaling pathway have positive effects on GC risk and prognosis.

Some studies have indicated that clinical pathological characteristics and adjuvant therapy would affect overall survival, however, the phenomenon that not all patients with the same situations have the same survival time suggests genetic variations may also insert one foot. Several publications have showed the associations between the two in kinds of cancers which were further proved not to be illusions from the biological aspect. Even if no genetic main effects existed for bulks of SNPs, according to several studies, we believed SNPs of interest might collectively confer and modulate cancer outcome.

Our study could not find main effect for some SNPs which may clash with other studies. The reasons may be the limitations existing in our study. We observed that the combined effect of genetic variants in mTORC1 genes on a poorer survival of GC. We have the excuses to believe the situation is common that the effect of each SNP we studied is relatively weak. When multi-SNPs were combined, they jointly present a much stronger effect than any single SNP[@B36]. Previous genetic association studies also showed that human complex traits can be influenced by the cumulative effects of multiple common SNPs, each with small individual effect and little predictive value[@B37]. But beyond that, the relatively small sample sizes may provide limited statistical power to detect the week effect of single SNP on GC survival.

We need be caution when drawing a conclusion because some limitations exist in our study. Firstly, the sample size was relatively small, especially for the low MAF of two SNPs (rs1882965 and rs2536), so we could not have enough power to calculate weak effects of genetic variants on clinical outcomes. Secondly, only eight SNPs were included in our study, some important genetic variants may be neglected. Thirdly, this is a retrospective study with inherent defects which may introduce selection bias or information bias. Finally, functional mechanisms underlying genetic variants influence on clinical outcomes could not be elucidated, which may confuse us it is a real association or just an illusion, although some studies have shown mTOR SNPs might affect gene expression, or modulating transcriptional activity, miRNA binding and splicing[@B36].

In conclusion, our findings demonstrate that genetic variants in mTORC1 genes may influence GC prognosis in Chinese populations. Further studies with larger sample size, more rigorous and prospective studies are required to confirm our findings.

This study was supported by funding from the Science and Technology Commission of Shanghai Municipality, China (Grant No.15ZR1427700), Shanghai Municipal Commission of Health and Family Planning (Grant No. 201540271) and China-Canada Joint Effort Program (Grant No. 2014DFG31460). We thank Dr. Qingyi Wei from Duke University Medical Center for his assistance in scientific editing and Ming Jia from Fudan University for his technical support.

mTORC1

:   mammalian target of rapamycin complex 1

GC

:   gastric cancer

OS

:   overall survival

SNP

:   single nucleotide polymorphism

HR

:   hazard ratio

CI

:   confidence interval

TNM

:   tumor-node-metastasis

MLST8

:   mammalian lethal with sec-13 protein 8

RPTOR

:   the regulatory-associated protein of MTOR

PI3K

:   phosphoinositide 3-kinase

4E-BP1

:   eIF4E binding protein 1

S6K1

:   ribosomal protein S6 kinases

AJCC

:   American Joint Commission on Cancer

MAF

:   minor allele frequency

CHB

:   Chinese Han, Beijing

TFBS

:   transcription factor binding site

LD

:   linkage disequilibrium

3\'UTR

:   3\'-untranslated region

5\'UTR

:   5\'-untranslated region

MST

:   median survival time

AML

:   acute myeloid leukemia.

![Survival plot of GC patients with different No. of at-risk genotypes.](jcav09p1448g001){#F1}

![Survival plot of GC patients with No. of at-risk genotypes less than or equal to 3 and greater than 3.](jcav09p1448g002){#F2}

###### 

Clinical characteristics of gastric cancer patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                                               Patients\    Deaths\     MST\       \              HR (95% CI)\        \           HR (95% CI)\       \
  Variable                                        N=197 (%)    N=85 (%)    (months)   Log-rank *P*   univariate          *P* value   multivariate       *P* value^2^
  ----------------------------------------------- ------------ ----------- ---------- -------------- ------------------- ----------- ------------------ --------------
  Age (years)                                                                                                                                           

  ≤65                                             113 (57.4)   41 (48.2)   42.55^1^   0.014          1.00                0.016       1.00               0.493

  \>65                                            84 (42.6)    44 (51.8)   40.00                     1.69 (1.11-2.59)                1.21 (0.70-2.08)   

  Sex                                                                                                                                                   

  Male                                            129 (65.5)   57 (67.1)   56.53      0.568          1.00                0.568       1.00               0.065

  Female                                          68 (34.5)    28 (32.9)   35.00^1^                  0.88 (0.56-1.38)                0.64 (0.39-1.03)   

  Drinking status                                                                                                                                       

  No                                              173 (87.8)   77 (90.6)   38.97^1^   0.266          1.00                0.270       1.00               0.549

  Yes                                             24 (12.2)    8 (9.4)     44.24^1^                  0.66 (0.32-1.38)                0.79 (0.37-1.70)   

  Tumor size (cm)                                                                                                                                       

  ≤ 4                                             113 (57.4)   35 (41.2)   42.88^1^   \<0.001        1.00                \<0.001     1.00               0.029

  \> 4                                            84 (42.6)    50 (58.8)   35.10                     2.33 (1.51-3.59)                1.70 (1.06-2.74)   

  Tumor site                                                                                                                                            

  Cardia                                          21 (10.7)    11 (12.9)   40.30      0.312          1.00                0.314       1.00               0.158

  Non-cardia                                      176 (89.3)   74 (87.1)   40.34^1^                  0.72 (0.38-1.36)                0.62 (0.32-1.20)   

  Tumor differentiation                                                                                                                                 

  Well/Moderate                                   47 (23.9)    17 (20.0)   42.23^1^   0.200          1.00                0.203       1.00               0.427

  Poor                                            150 (76.1)   68 (80.0)   56.53                     1.41 (0.83-2.41)                0.80 (0.45-1.40)   

  Depth of invasion                                                                                                                                     

  T1/T2                                           66 (33.5)    7 (8.2)     50.87^1^   \<0.001        1.00                \<0.001     1.00               0.017

  T3/T4                                           131 (66.5)   78 (91.8)   33.27                     7.71 (3.55-16.72)               3.25 (1.23-8.58)   

  Lymph node metastasis                                                                                                                                 

  N0                                              72 (36.5)    15 (17.6)   35.24^1^   \<0.001        1.00                \<0.001     1.00               0.911

  N1/N2/N3                                        125 (63.5)   70 (82.4)   38.53                     3.23 (1.85-5.64)                0.94 (0.33-2.73)   

  Distant metastasis                                                                                                                                    

  M0                                              193 (98.0)   81 (95.3)   40.31^1^   \<0.001        1.00                0.001       1.00               0.271

  M1                                              4 (2.0)      4 (4.7)     11.30                     5.26 (1.90-14.62)               1.87 (0.61-5.68)   

  TNM stage                                                                                                                                             

  I/II                                            97 (49.2)    20 (23.5)   47.07^1^   \<0.001        1.00                \<0.001     1.00               \<0.001

  III/IV                                          100 (50.8)   65 (76.5)   23.55                     4.27 (2.58-7.07)                3.63 (2.08-6.34)   

  Vascular/Lymphatic vessel/Perineural invasion                                                                                                         

  No                                              152 (77.2)   53 (62.4)   43.69^1^   \<0.001        1.00                \<0.001     1.00               \<0.001

  Yes                                             45 (22.8)    32 (37.6)   18.17                     3.05 (1.95-4.76)                2.44 (1.51-3.94)   

  Chemotherapy                                                                                                                                          

  No                                              95 (48.2)    42 (49.4)   51.27      0.408          1.00                0.408       1.00               0.036

  Yes                                             102 (51.8)   43 (50.6)   41.20^1^                  0.84 (0.55-1.28)                0.55 (0.31-0.96)   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MST, median survival time; HR, hazard ratio; CI, confidence interval.

[@B1] Mean survival time was provided when MST could not be calculated.

[@B2] Adjusted for age, sex, drinking status, tumor size, tumor site, tumor differentiation, TNM stage, vascular/lymphatic vessel/perineural invasion, chemotherapy.

###### 

Correlations between different genotypes of genes in mTORC1 pathway and gastric cancer patients\' survival

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                             \           Patients\   Deaths\   MST\       \              HR (95%CI)\         \           HR (95%CI)\          \
  SNP\'s genes                  Genotypes   (N=197)     (N=85)    (months)   Log-rank *P*   univariate          *P* value   multivariate         *P* value^2^
  ----------------------------- ----------- ----------- --------- ---------- -------------- ------------------- ----------- -------------------- --------------
  *mTOR* rs1883965              GG          167         72        39.73^1^   0.995          1.00                0.995       1.00                 0.270

  (G wild type)                 GA          30          13        34.33^1^                  1.00 (0.56-1.81)                1.41 (0.77-2.58)     

  *mTOR* rs2536                 TT          161         67        40.55^1^   0.470          1.00                            1.00                 

  (T wild type)                 TC          32          17        34.50                     1.35 (0.79-2.31)    0.265       1.34 (0.74-2.42)     0.332

                                CC          4           1         6.23^1^                   0.64 (0.09-4.61)    0.658       1.26 (0.17-9.37)     0.818

                                TC/CC       36          18        36.93                     1.28 (0.76-2.15)    0.361       1.34 (0.75-2.37)     0.325

                                TT/TC       193         84        39.67^1^   0.616          1.00                            1.00                 

                                CC          4           1         6.23^1^                   0.61 (0.08-4.36)    0.620       1.20 (0.16-8.87)     0.858

  *MLST8* rs26865               AA          56          21        56.53      0.344          1.00                            1.00                 

  (A wild type)                 AG          68          33        54.43                     1.49 (0.86-2.58)    0.151       1.47 (0.83-2.58)     0.184

                                GG          73          31        33.42^1^                  1.22 (0.70-2.12)    0.487       1.08 (0.60-1.94)     0.802

                                AG/GG       141         64        37.06^1^                  1.35 (0.82-2.20)    0.238       1.27 (0.75-2.12)     0.375

                                AA/AG       124         54        56.53      0.897          1.00                            1.00                 

                                GG          73          31        33.42^1^                  0.97 (0.62-1.51)    0.897       0.86 (0.54-1.37)     0.516

  *MLST8* rs3160                TT          51          26        51.27      0.335          1.00                            1.00                 

  (T wild type)                 TC          88          39        54.50                     0.88 (0.54-1.45)    0.616       1.02 (0.60-1.74)     0.930

                                CC          58          20        31.80^1^                  0.65 (0.36-1.17)    0.149       0.69 (0.37-1.28)     0.236

                                TC/CC       146         59        38.98^1^                  0.79 (0.50-1.25)    0.307       0.88 (0.54-1.44)     0.610

                                TT/TC       139         65        54.50      0.167          1.00                            1.00                 

                                CC          58          20        31.80^1^                  0.70 (0.43-1.16)    0.169       0.68 (0.40-1.15)     0.150

  *RPTOR* rs1062935             TT          48          18        42.85^1^   0.431          1.00                            1.00                 

  (T wild type)                 TC          101         42        36.47^1^                  1.20 (0.69-2.08)    0.527       0.85 (0.46-1.55)     0.588

                                CC          48          25        54.43                     1.48 (0.81-2.72)    0.204       1.53 (0.81-2.89)     0.186

                                TC/CC       149         67        37.73^1^                  1.29 (0.77-2.17)    0.341       1.06 (0.61-1.85)     0.842

                                TT/TC       149         60        40.51^1^   0.253          1.00                            1.00                 

                                CC          48          25        54.43                     1.31 (0.82-2.09)    0.254       *1.71 (1.04-2.82)*   *0.033*

  *RPTOR* rs12602885            GG          100         42        39.20      0.495          1.00                            1.00                 

  (G wild type)                 GA          79          32        38.16^1^                  0.95 (0.60-1.50)    0.812       0.78 (0.48-1.28)     0.331

                                AA          18          11        46.65                     1.42 (0.73-2.76)    0.303       1.21 (0.61-2.43)     0.584

                                GA/AA       97          43        54.50                     1.03 (0.68-1.58)    0.878       0.87 (0.56-1.37)     0.548

                                GG/GA       179         74        40.01^1^   0.245          1.00                            1.00                 

                                AA          18          11        46.65                     1.45 (0.77-2.74)    0.248       1.34 (0.79-2.61)     0.385

  *RPTOR* rs3751932             TT          144         65        37.73^1^   0.626          1.00                            1.00                 

  (T wild type)                 TC          40          14        35.67^1^                  0.75 (0.42-1.34)    0.336       0.83 (0.46-1.50)     0.539

                                CC          13          6         56.53                     0.93 (0.40-2.15)    0.871       1.43 (0.60-3.39)     0.420

                                TC/CC       53          20        56.53                     0.80 (0.48-1.32)    0.381       0.95 (0.57-1.59)     0.850

                                TT/TC       184         79        38.43^1^   0.976          1.00                            1.00                 

                                CC          13          6         56.53                     0.99 (0.43-2.27)    0.976       1.47 (0.62-3.48)     0.377

  *RPTOR* rs3751934             AA          51          24        54.43      0.393          1.00                            1.00                 

  (A wild type)                 AC          59          21        29.72^1^                  0.69 (0.38-1.25)    0.220       0.74 (0.41-1.36)     0.333

                                CC          87          40        56.53                     0.96 (0.58-1.59)    0.865       0.93 (0.55-1.58)     0.786

                                AC/CC       146         61        40.20^1^                  0.85 (0.53-1.36)    0.488       0.85 (0.52-1.40)     0.529

                                AA/AC       110         45        39.43^1^   0.506          1.00                            1.00                 

                                CC          87          40        56.53                     1.16 (0.75-1.77)    0.507       1.08 (0.70-1.68)     0.720

  No. of at-risk genotypes^3^                                                                                                                    

  0                                         17          4         20.57^1^   0.033          1.00                            1.00                 

  1                                         46          18        38.85^1^                  1.67 (0.57-4.95)    0.351       1.82 (0.61-5.46)     0.283

  2                                         79          37        56.53                     2.23(0.80-6.27)     0.127       2.71 (0.96-7.68)     0.061

  3                                         39          14        38.05^1^                  1.57 (0.52-4.78)    0.424       2.31 (0.74-7.20)     0.147

  4                                         13          9         40.00                     3.28 (1.01-10.67)   0.049       4.69 (1.42-15.52)    0.011

  5                                         3           3         15.50                     7.46 (1.65-33.65)   0.009       9.53 (2.00-45.49)    0.005

  Trend                                                                                                         0.033                            0.002

  Dichotomized groups                                                                                                                            

  0-3                                       181         73        40.60^1^   0.015          1.00                            1.00                 

  4-5                                       16          12        21.20                     2.11 (1.14-3.88)    0.017       *2.44 (1.30-4.58)*   *0.006*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MST, median survival time; HR, hazard ratio; CI, confidence interval.

[@B1] Mean survival time was provided when MST could not be calculated.

[@B2] Adjusted for age, sex, drinking status, tumor size, tumor site, tumor differentiation, TNM stage, vascular/lymphatic vessel/perineural invasion, chemotherapy.

[@B3] The risk genotypes used for the calculation were *mTOR* rs1883965 GA + rs2536 TC/CC, *MLST8* rs26865 AG + rs3160 TC, *RPTOR* rs1062935 TT/TC + rs12602885 GG/GA + rs3751932 TT/TC + rs3751934 AA/AC.
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